Abstract 64P
Background
Colo rectal cancer is the third most common cancer in the world. Clinical data on localized colon cancer and treatment outcome is scarce in the literature. This is a real-world study of the clinical profile and treatment patterns and outcomes of patients with nonmetastatic colon cancer from India. Here we report our experience in this patient population.
Methods
This is a retrospective chart review of patients with nonmetastatic colon cancer registered in our hospital from May 2011 to December 2021. Patients who presented with recurrent metastatic disease were included in this review if the treatment details for the localized disease were available. The baseline demographic features and treatment details and toxicity were recorded.
Results
Total of 1084 patients were registered during this time period. The median age of the population was 60 (9-91 )years. Males constituted 648 (60%) of cases. The most common site of the primary was descending and sigmoid colon (41%). Majority of the patients had stage III disease (46.5%). Most of our patients received capecitabine and oxaliplatin-based combination therapy. The median disease-free survival is 30.7 months.
Conclusions
Most common site of colon cancer is the left side and stage III is the most common stage of presentation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02